UK genomics market valued at over £5bn, according to new report
Pharma Times
JULY 30, 2021
‘Genomics Nation’ report launched in a bid to showcase the thriving UK genomics sector
Modernizing cell culture processes for the next wave of genomic medicine
Pharmaceutical Technology
FEBRUARY 3, 2023
The field of genomic medicine has reached a true turning point. Cell culture challenges The viral vectors used in the gene therapies currently on the market are produced in adherent human embryonic HEK-293 cell culture. One important advancement will involve tackling the still-present issue of empty capsids, for example.
Genome 
244
244 Join 21,000+
Insiders
Sign Up for our Newsletter
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
How Will Ultima Genomics and Genome Insight Make WGS Affordable?
XTalks
APRIL 21, 2023
The application of whole genome sequencing (WGS) to derive a more complete understanding of cancer has been a central goal of cancer researchers even before the first human genome was decoded in 2003. Ultima Genomics has already partnered with other leading biotech startups.
Genomics 97
97 
Micro-robots, smart toilets, and 3D bioprinted organs: the future of healthcare
Pharmaceutical Technology
SEPTEMBER 22, 2022
You have just received the results from your whole genome sequencing test, offered through your public health provider, and discovered that you have a 75% chance of developing a rare form of cancer. It could be that you are lucky, and there is already a cancer vaccine on the market that you will get priority for. It is the year 2030.
Genomics 342
342 
Investment fuels AI-driven development of breakthrough genomic medicines
pharmaphorum
OCTOBER 12, 2022
David Del Bourgo (CEO and co-founder, Whitelab Genomics) has always been passionate about introducing disruptive, innovative technologies to markets. We founded Whitelab Genomics after realising the potential to use data, data science, and AI in a more systematic way to develop genomic therapies,” Del Bourgo says.
Genomics 105
105 
STAT+: ??Genomics is racing toward a $100 genome. Are we ready for it?
STAT News
JULY 27, 2022
As the cost of DNA sequencing plummets, we’re fast approaching a point when decoding a human genome could cost $100 — about as much as the average American’s weekly grocery store run. Health systems are preparing to test programs that could lead to the use of whole-genome screening in millions of newborns.
Genome 105
105 
Verge Genomics takes AI-sourced drug for ALS into clinic
pharmaphorum
OCTOBER 31, 2022
Verge Genomics has joined a select group of biotechs who have taken a drug discovered and developed using artificial intelligence into human testing. The post Verge Genomics takes AI-sourced drug for ALS into clinic appeared first on. Alice Zhang.
Genome 136
136 
Genome Edited Foods: Understanding the New FDA Guidance
XTalks
MARCH 1, 2024
In a pivotal move for the food industry, the US Food and Drug Administration (FDA) has unveiled industry guidance for genome edited foods derived from plants. This landmark guidance aims to demystify the FDA’s risk-based approach towards both genome edited foods and all new plant varieties. What is Genome Editing?
Genomics 86
86 
Illumina placed on China’s ‘unreliable entity’ list
Bio Pharma Dive
FEBRUARY 5, 2025
and as Illumina faces stiff competition in China’s genome sequencing market. Analysts said the move comes amid rising trade tensions with the U.S.
Genome 154
154 
STAT+: Chinese DNA giant’s U.S. affiliate looks to rival Illumina, touting $100 genome and high-power sequencers
STAT News
FEBRUARY 7, 2023
Complete Genomics, a U.S. firm affiliated with Chinese sequencing giant BGI, on Tuesday announced plans to launch a new line of sequencers it says can decode DNA in larger amounts — and at lower costs — than any instrument on the market.
Genomics 98
98 
Opinion: Where are the guidelines for the production of animals with intentional genomic alterations?
STAT News
APRIL 17, 2023
Salmon that reach market size in 18 months instead of 30. But with the advent of genetic engineering, genes encoding favorable traits in one species (say, that hornless cow) could be spliced into the genomes of other animals. Pigs that are less likely to induce allergic reactions in humans. Read the rest…
Genomics 98
98 
German program using whole genome sequencing to diagnose rare diseases and cancer risk
BioPharma Reporter
FEBRUARY 25, 2021
A program at the University Hospital of TÃbingen is the first in Germany to use whole genome sequencing (WGS) to improve the diagnosis of rare diseases and hereditary cancers.
Genome 98
98 
UK-wide whole genome sequencing for newborns is feasible – but there are some key questions to answer first
pharmaphorum
NOVEMBER 23, 2021
Genomics England, the Department of Health and Social Care’s genome-sequencing hub, has this year announced that support for whole genome sequencing (WGS) has reached a level at which its national rollout on the NHS may someday become a reality. Only when genomic databases are diverse can we ensure that we all benefit equally.
Genomics 116
116 
The future of the gene therapy market: driving innovations in biotherapeutics
Pharmaceutical Technology
OCTOBER 26, 2022
The biotherapeutics market is rapidly growing, with 2021 seeing the highest-ever cell and gene therapy approval number. New doors were opened in the 2000s with the development of genome editing, such as CRISPR-Cas9, which introduces molecular tools to change existing DNA. The future of cell and gene therapies.
Gene Therapy 130
130 
10x Genomics Enters In Situ Analysis Market with Recent Acquisitions
BioSpace
OCTOBER 7, 2020
10X Genomics just agreed to acquire ReadCoor, Inc., The $350 million deal comes on the heels of 10x Genomics’ August acquisition of CartaNA AB, a Stockholm-based developer of in situ RNA analysis technology. an innovator in the nascent field of in situ technology.
Genome 57
57 
What We’re Watching for 2024 – Top Trends in Market Access
Intouch Solutions
NOVEMBER 20, 2023
In the rapidly changing landscape of global markets, staying ahead of the curve is crucial for businesses aiming to expand and thrive. As we step into 2024, the realm of market access undergoes dynamic shifts influenced by technological advancements, policy changes, and evolving consumer behaviors.
Marketing 105
105 
How did pharma develop a vaccine so quickly?
World of DTC Marketing
DECEMBER 29, 2020
Both the Pfizer and Moderna vaccines copied RNA sequence from the virus genome and found a way to manufacture it at scale with high-level processes and quality control. It’s estimated that the COVID 19 vaccine market could be worth almost $100 billion. 1455NO-HEALTH-CORONAVIRUS_VACCINES_PFIZER_O_.
Vaccine 307
307 
UK agency pilots biobank to study links between genetics and drug side effects
Pharmaceutical Technology
MAY 25, 2023
The Yellow Card biobank will launch as a joint venture with the UK-government funded entity Genomics England on June 1. The pilot phase of the project will focus on the drug allopurinol, which is used to treat gout by lowering uric acid in your blood and is marketed by several companies including Aspen Pharmacare as Zyloric in the UK.
Biobanking 130
130 
Whole Genome And Exome Sequencing Markets, Q4 2021 Market Report – ResearchAndMarkets.com
BioTech 365
OCTOBER 5, 2021
Whole Genome And Exome Sequencing Markets, Q4 2021 Market Report – ResearchAndMarkets.com Whole Genome And Exome Sequencing Markets, Q4 2021 Market Report – ResearchAndMarkets.com DUBLIN–(BUSINESS WIRE)–The “Whole Genome And Exome Sequencing Markets” report has been added to ResearchAndMarkets.com’s offering. (..)
Genomics 40
40 
Congenica extends contract with Hong Kong Genome Project
BioPharma Reporter
OCTOBER 9, 2023
Congenica, a digital health company providing software and solutions for the analysis and interpretation of genomic data at scale, has announced a two-year extension to its contract for the Hong Kong Genome Project (HKGP), the first large-scale genome sequencing initiative in Hong Kong.
How epilepsy researchers are moving the needle past anti-seizure treatments
Pharmaceutical Technology
FEBRUARY 13, 2023
With the latest advances in whole genome sequencing , it is increasingly clear that rare epilepsies are largely caused by a single genomic mutation, says Ferraro. New developments in the anti-seizure pipeline Genomic screenings can also be used to sharpen the efficacy of already available treatments.
Research 264
264 
AstraZeneca’s Alexion acquires genomic medicine company
BioPharma Reporter
OCTOBER 4, 2022
Alexion, AstraZeneca Rare Disease will acquire LogicBio Therapeutics, an American genomic medicine company.
Genome 59
59 
Global Genome Editing Market Segment Forecasts 2021-2028: Cell Line Engineering Dominates the Market – ResearchAndMarkets.com
BioTech 365
SEPTEMBER 6, 2021
Global Genome Editing Market Segment Forecasts 2021-2028: Cell Line Engineering Dominates the Market – ResearchAndMarkets.com Global Genome Editing Market Segment Forecasts 2021-2028: Cell Line Engineering Dominates the Market – ResearchAndMarkets.com DUBLIN–(BUSINESS WIRE)–The “Global Genome Editing Market Size, Share (..)
Genomics 40
40 
Global Optical Genome Mapping Market Competition Forecast & Opportunities 2021-2026 – ResearchAndMarkets.com
BioTech 365
OCTOBER 4, 2021
Global Optical Genome Mapping Market Competition Forecast & Opportunities 2021-2026 – ResearchAndMarkets.com Global Optical Genome Mapping Market Competition Forecast & Opportunities 2021-2026 – ResearchAndMarkets.com DUBLIN–(BUSINESS WIRE)–The “Global Optical Genome Mapping Market By Component (Instruments v/s (..)
Genome 40
40 
FDA Makes Low-Risk Determination for Marketing of Products from Genome-Edited Beef Cattle After Safety Review
The Pharma Data
MARCH 7, 2022
Decision Regarding Slick-Haired Cattle is Agency’s First Enforcement Discretion Decision for an Intentional Genomic Alteration in an Animal for Food Use. IGAs are alterations made using molecular technologies that introduce changes to the genome of an animal. Today, the U.S. Solomon, D.V.M., Related Information.
Genomics 52
52 
Stevenage Bioscience Catalyst launches accelerator program for biotech start-ups
BioPharma Reporter
MARCH 3, 2022
Stevenage Bioscience Catalyst (SBC) has launched an accelerator program for biotech start-ups focusing on data-enabled drug discovery, genomics and advanced therapies: aiming to give such companies the skills they need to get potential new drugs and therapies to market more quickly.
Genome 111
111 
Bringing in Light Genome Editing Techniques: ZFN, TALEN and Meganucleases
Roots Analysis
FEBRUARY 15, 2022
Gene engineering based on recombination was pioneered in the mid-1990s; Currently, development of gene editing technologies has opened up the possibility of modifying genomic sequences in both eukaryotic and prokaryotic organisms. Genome Editing is a way of making changes in the DNA. Type of Genome Editing: Zinc-Finger Nuclease.
Genomics 52
52 
Realising the promise of genomic testing across oncology
pharmaphorum
AUGUST 4, 2022
Unlocking the secrets of the human genome has long been an ambitious pursuit for researchers around the world. Today, the landscape of genomic testing and research is rapidly progressing, with significant scientific and technological advances driving a paradigm shift in the understanding of oncology at a molecular level.
Genomics 52
52 
Medical Device & MedTech Layoffs in 2025: A Roundup
XTalks
MARCH 13, 2025
In 2025, as market pressures intensify and companies refocus on core strategic priorities, medical device and medtech companies have been forced to make tough decisions regarding their workforces. This targeted reorganization is designed to align resources with its core genomics priorities.
Genome 66
66 
Genome Editing/Genome Engineering Market Research Report 2021: Technology (CRISPR, TALEN, ZFN, Antisense), Product & Service, Application (Cell Line Engineering, Genetic Engineering, Diagnostics) – ResearchAndMarkets.com
BioTech 365
DECEMBER 20, 2021
Genome Editing/Genome Engineering Market Research Report 2021: Technology (CRISPR, TALEN, ZFN, Antisense), Product & Service, Application (Cell Line Engineering, Genetic Engineering, Diagnostics) – ResearchAndMarkets.com Genome Editing/Genome Engineering Market Research Report 2021: Technology (CRISPR, TALEN, ZFN, Antisense), Product & (..)
STAT+: Pacific Biosciences, known for niche DNA sequencing, looks to rival Illumina with new product launch
STAT News
OCTOBER 25, 2022
firm best known for its niche approach to DNA sequencing, on Tuesday announced plans to launch a new product that will put the company in direct competition with genomics juggernaut Illumina. The new DNA sequencer, dubbed Onso, reads the genome in small pieces and uses software to stitch that information together.
DNA 98
98 
Spatial Genomics, Transcriptomics and Proteomics Solutions – An Amelioration of Tissue Analytics
Roots Analysis
AUGUST 28, 2022
The up-and-coming field of spatial genomics in biology promises to bridge the gap between high plex, high throughput, and high resolution. 70+ spatial Genomics solutions are developed by industry and non-industry players. 70+ spatial Genomics solutions are developed by industry and non-industry players. Concluding Remarks.
Genomics 52
52 
Illumina and Sequoia Capital China Partner to Launch Genomics Incubator in China
The Pharma Data
JANUARY 31, 2021
(NASDAQ: ILMN), the global leader in DNA sequencing and array-based technologies, and Sequoia Capital China , a leading investment firm, today announced a collaboration to catalyze the startup ecosystem in China with the launch of the Sequoia Capital China Intelligent Healthcare Genomics Incubator, Powered by Illumina.
Genomics 52
52 
Rare Disease Spotlight – tracing the rise of orphan drug designations over almost 40 years
Pharmaceutical Technology
JUNE 29, 2022
Orphan drug designations provide financial incentives for companies and developers, including “tax credits for qualified clinical testing”, “a Waiver of the Prescription Drug User Fee” that is currently at almost $3 million for a new drug, and “potential seven years of market exclusivity”.
Drugs 246
246 
Global Sequencing Reagents Market (2021 to 2028) – Featuring Agilent Technologies, BGI Genomics and Qiagen Among Others – ResearchAndMarkets.com
BioTech 365
NOVEMBER 19, 2021
Global Sequencing Reagents Market (2021 to 2028) – Featuring Agilent Technologies, BGI Genomics and Qiagen Among Others – ResearchAndMarkets.com Global Sequencing Reagents Market (2021 to 2028) – Featuring Agilent Technologies, BGI Genomics and Qiagen Among Others – ResearchAndMarkets.com DUBLIN–(BUSINESS WIRE)–The (..)
Reagent 40
40 
Gene editing: beyond the hype
pharmaphorum
JANUARY 29, 2021
Genome editing is an exciting but still nascent field, and companies in the area face as many obstacles as they do opportunities. ZFPs can be engineered to make zinc finger nucleases, or ZFNs, which are proteins that can be used to edit genomes by knocking select genes in or out to specifically modify DNA sequences.
Gene Editing 145
145 
Vivlion GmbH Signs Worldwide License Agreement With ERS Genomics for CRISPR/Cas9 Patent Portfolio
The Pharma Data
NOVEMBER 30, 2020
The license from ERS Genomics now enables Vivlion to offer both R&D reagents and screening services to its customers worldwide. “The The unique 3Cs technology developed by Vivlion significantly expands the use of CRISPR/Cas libraries for target discovery and drug development,” said Eric Rhodes, CEO of ERS Genomics. “It
Genomics 52
52 
Worldwide Genomics Industry to 2026 – Featuring Agilent Technologies, Bayer Aktiengesellschaft and BGI Genomics Among Others – ResearchAndMarkets.com
BioTech 365
SEPTEMBER 2, 2021
Worldwide Genomics Industry to 2026 – Featuring Agilent Technologies, Bayer Aktiengesellschaft and BGI Genomics Among Others – ResearchAndMarkets.com Worldwide Genomics Industry to 2026 – Featuring Agilent Technologies, Bayer Aktiengesellschaft and BGI Genomics Among Others – ResearchAndMarkets.com DUBLIN–(BUSINESS WIRE)–The (..)
Genome 40
40 
Rome Therapeutics adds $72 million to Series B round to harness “dark genome”
Outsourcing Pharma
SEPTEMBER 14, 2023
company Rome Therapeutics plans to use the proceeds of its $72 million Series B round to take an experimental autoimmune disease treatment through early clinical testing.
Genome 103
103 
Genome Editing Market Update: Intellia Therapeutics Presents Data at the 2019 Annual Congress of the European Society of Gene and Cell Therapy
Roots Analysis
FEBRUARY 27, 2024
The global genome editing market is anticipated to grow at a CAGR of 12.6% The global genome editing market is anticipated to grow at a CAGR of 12.6% The immense benefits offered by CRISPR makes it one of the most preferred genome editing approach. during the forecast period 2023-2035.
Genomics 40
40 
Singapore provides access to ‘top global talent’, says 10x Genomics
BioPharma Reporter
NOVEMBER 10, 2021
The company recently opened a manufacturing and commercial hub in Singapore, making the facility its first outside of the US.
Genome 92
92 
BIO comments on FDA draft guidance for human gene therapy products incorporating human genome editing
BioPharma Reporter
JUNE 23, 2022
BIO, the worldâs largest trade association for the biotech industry, has responded to the US Food and Drug Administration's draft guidance on developing human gene therapy products that incorporate genome editing (GE) of human somatic cells.
Gene Therapy 59
59 
Broken String Biosciences bags $15M to make genome editing safer
BioPharma Reporter
SEPTEMBER 19, 2023
The UK startup Broken String Biosciences has raised a $15 million Series A round to fund the development of a DNA sequencing platform that maps off-target DNA breaks resulting from genome editing technology.
Genome 52
52 
Let's personalize your content